3 completed, 1 recruiting. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Urinary Bladder, Underactive: new trials by email Literature Review of Urinary Bladder, Underactive trials Research Report on Urinary Bladder, Underactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB) SFG-02, Placebo - Participants With Underactive Bladder (UAB) | Phase 2 | Recruiting | Juro Sciences Inc. | 70 | 2026-08-22 | 2026-10-30 |
| Delta Q Value to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction Uroflowmetry - Urinary Obstruction, Detrusor Underactivity | Phase 2 / Phase 3 | Completed | Ain Shams University | 238 | 2019-01-01 | 2022-05-03 |
| A Study of ASP8302 in Participants With Underactive Bladder ASP8302, Placebo - Underactive Bladder | Phase 2 | Completed | Astellas Pharma Europe B.V. | 135 | 2018-11-20 | 2024-11-21 |
| Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. TAC-302, Placebo - Detrusor Underactivity, Overactive Bladder | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 195 | 2017-09-09 | 2025-01-20 |
Lower Urinary Tract Symptoms (1) · Urinary Bladder, Overactive (1) · Vitreoretinopathy, Proliferative (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urological Manifestations (4) · Lower Urinary Tract Symptoms (3) · Eye Diseases (1) · Retinal Diseases (1)
tac-302 (1)
Ain Shams University (1) · Astellas Pharma Europe B.V. (1) · Juro Sciences Inc. (1) · Taiho Pharmaceutical Co., Ltd. (1)
Japan (3) · Egypt (1) · Germany (1) · Netherlands (1) · Poland (1) · Slovakia (1) · United Kingdom (1)
2017 (1)